Oxford Biomedica PLC Director Dealings / Market Share Purchase (9394Z)
December 20 2017 - 5:22AM
UK Regulatory
TIDMOXB
RNS Number : 9394Z
Oxford Biomedica PLC
20 December 2017
Director Dealings / Market Share Purchase
Oxford, UK - 20 December 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the
Group, on Wednesday 20 December 2017 acquired ordinary shares in
the Group as set out below under the market share purchase
agreement outlined in the Group's announcement on 15 December
2015.
Under the market share purchase agreement, one-third of Dr
Tallarigo's fees as Chairman, after tax, are to be used to purchase
shares in Oxford BioMedica PLC on a monthly basis at the prevailing
market price.
Interest after
purchase
----------- --------- ---------- ---------------- ----------------------------
Director Title Price Number of Number % of total
/ PDMR per share Ordinary Shares of Ordinary issued
(p) acquired Shares share capital
----------- --------- ---------- ---------------- ------------ --------------
Dr Lorenzo
Tallarigo Chairman 9.0p 29,365 2,173,087 0.07%
----------- --------- ---------- ---------------- ------------ --------------
The issued share capital of the Group is 3,107,136,542 ordinary
1p shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Stuart Paynter, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Philippa Gardner/Laura
Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 280 people. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHURUARBRAUUAA
(END) Dow Jones Newswires
December 20, 2017 06:22 ET (11:22 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024